MDMA, "molly", "ecstasy", or 3,4-Methylenedioxymethamphetamine, has been labeled a Schedule I drug under the controlled Substances Act since 1985. This classification has the potential to change with new research conducted by MAPS. The Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS is looking to study MDMA, as well as LSD and Psilocybin's application in treating mental disorders such as anxiety, addiction, depression and PTSD. Out of all the subjects who participated in the phase 2 trial of MDMA years ago with PTSD, 83% show no more signs of PTSD after use of MDMA. MAPS is expecting approval by the FDA for phase 3 trials of MDMA this summer, hoping to get recognized accepted medical use, taking off MDMA from the Schedule 1 classification, and hopefully allowing for legal MDMA therapy.
http://www.maps.org/
https://www.vice.com/en_us/article/wj8wwy/legal-mdma-therapy-could-be-just-a-few-years-away